Adaptive randomization of veliparib-carboplatin treatment in breast cancer

New England Journal of Medicine

Volumn 375, Issue 1, 2016, Pages 23-34

  Rugo, Hope S ^a   Olopade, Olufunmilayo I ^g   DeMichele, Angela ⁱ   Yau, Christina ^a,c   Van't Veer, Laura J ^a   Buxton, Meredith B ^a   Hogarth, Michael ^d   Hylton, Nola M ^a   Paoloni, Melissa ^b   Perlmutter, Jane ^j   Symmans, W Fraser ^k   Yee, Douglas ⁿ   Chien, A Jo ^a   Wallace, Anne M ^e   Kaplan, Henry G ^p   Boughey, Judy C ^o   Haddad, Tufia C ^o   Albain, Kathy S ^h   Liu, Minetta C ^q   Isaacs, Claudine ^q   Khan, Qamar J ^r   Lang, Julie E ^s   Viscusi, Rebecca K ^s   Pusztai, Lajos ^k   Moulder, Stacy L ^k   Chui, Stephen Y ^u   Kemmer, Kathleen A ^u   Elias, Anthony D ^v   Edmiston, Kirsten K ^w   Euhus, David M ^l   Haley, Barbara B ^l   Nanda, Rita ^g   Northfelt, Donald W ^t   Tripathy, Debasish ^f   Wood, William C ^x   Ewing, Cheryl ^a   Schwab, Richard ^e   Lyandres, Julia ^a   Davis, Sarah E ^a   Hirst, Gillian L ^a   Sanil, Ashish ^m   Berry, Donald A ^k,m   Esserman, Laura J ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Quantum Leap Healthcare Collaborative   (United States)

^c BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h LOYOLA UNIVERSITY CHICAGO   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j Gemini Group   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^m BERRY CONSULTANTS   (United States)

ⁿ UNIVERSITY OF MINNESOTA   (United States)

^o MAYO CLINIC   (United States)

^p SWEDISH MEDICAL CENTER   (United States)

^q GEORGETOWN UNIVERSITY   (United States)

^r UNIVERSITY OF KANSAS   (United States)

^s UNIVERSITY OF ARIZONA   (United States)

^t MAYO CLINIC   (United States)

^u OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^v UNIVERSITY OF DENVER   (United States)

^w INOVA FAIRFAX HOSPITAL   (United States)

^x EMORY UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GANITUMAB; NERATINIB; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB; TREBANANIB; VELIPARIB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; BAYES THEOREM; BREAST CANCER; BREAST SURGERY; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; VOMITING; CLINICAL TRIAL; MIDDLE AGED; NEOADJUVANT THERAPY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; BENZIMIDAZOLES; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84978120246     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1513749     Document Type: Conference Paper

References (20)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Cortazar P, Geyer CE Jr Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol 2015; 22: 1441-6.
3. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and longterm clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-72.
4. Yee D, Haddad T, Albain K, et al. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol 2012; 30: 4584-6, author reply 4588-9.
5. DeMichele A, Yee D, Berry DA, et al. The neoadjuvant model is still the future for drug development in breast cancer. Clin Cancer Res 2015; 21: 2911-5.
6. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86: 97-100.
7. Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728-37.
8. Viale G, Slaets L, Bogaerts J, et al. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Ann Oncol 2014; 25: 816-23.
9. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2012; 9: 199-207.
10. Berry DA. The brave new world of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol 2015; 9: 951-9.
11. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov 2006; 5: 27-36.
12. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012; 366: 2438-41.
13. Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, version 1.2016. J Natl Compr Canc Netw 2015; 13: 1475-85.
14. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25: 4414-22.
15. Glas AM, Floore A, Delahaye LJ, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006; 7: 278-88.
16. Roepman P, Horlings HM, Krijgsman O, et al. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res 2009; 15: 7003-11.
17. Wolff D, Daemon A, Yau C, et al. MammaPrint ultra-high risk score is associated with response to neoadjuvant chemotherapy in the I-SPY1 trial (CALGB 150007/150012; ACRIN 6657). Cancer Res 2014; 73: 24 Suppl. abstract (http://cancerres.aacrjournals.org/content/73/24-Supplement/P1-08-01?cited-by= yes&legid=canres;73/24-Supplement/P1-08-01).
18. Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med 2016; 375:11-22.
19. von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15: 747-56.
20. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-perweek paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33: 13-21.